Sign In
Buy BHVN
$13.50
-0.320 (-2.32%)
At Close: Jul 31, 2026
Biohaven's Exciting Year Of Catalysts
05:14am, Friday, 28'th Feb 2025
Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial upsid
Why Biohaven Stock Triumphed on Tuesday
06:42pm, Tuesday, 11'th Feb 2025
News of a big and important regulator's move was the electricity that powered Biohaven (BHVN 11.19%) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational drug i
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck
05:47pm, Tuesday, 11'th Feb 2025
Biohaven's NDA for Troriluzole in spinocerebellar ataxia was accepted by the FDA with Priority Review, potentially leading to approval in Q3 2025. BHV-7000, a selective Kv7 activator, is being studied
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the pri
Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements across the MoDETM (molecular degraders of extracellula
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
05:54pm, Tuesday, 07'th Jan 2025
NEW HAVEN, Conn. , Jan. 7, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
02:23pm, Tuesday, 17'th Dec 2024
On Monday, Biohaven Ltd. BHVN revealed clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE) platform and its glutamate modulation and ion chann
BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300 achieved rapid and progressive lowering of IgG within h
Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated in ongoing Phase 2 and 3 clinical studies
Biohaven's Revenue Path: SCA And Obesity Therapies
05:30am, Friday, 29'th Nov 2024
Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treat
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
11:51am, Monday, 25'th Nov 2024
On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:32am, Monday, 25'th Nov 2024
U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.
Biohaven's spinal muscular atrophy drug fails to meet main goal in study
07:45am, Monday, 25'th Nov 2024
Biohaven said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve sta
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
07:30am, Monday, 25'th Nov 2024
In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
04:05pm, Tuesday, 12'th Nov 2024
Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial results from pivotal trial with troriluzole i
